CA2936974A1 - Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia - Google Patents

Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia Download PDF

Info

Publication number
CA2936974A1
CA2936974A1 CA2936974A CA2936974A CA2936974A1 CA 2936974 A1 CA2936974 A1 CA 2936974A1 CA 2936974 A CA2936974 A CA 2936974A CA 2936974 A CA2936974 A CA 2936974A CA 2936974 A1 CA2936974 A1 CA 2936974A1
Authority
CA
Canada
Prior art keywords
receptor antagonist
crf1 receptor
nbi
acth
crf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2936974A
Other languages
English (en)
French (fr)
Inventor
Dimitri E. Grigoriadis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52450623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2936974(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Priority to CA3155599A priority Critical patent/CA3155599A1/en
Publication of CA2936974A1 publication Critical patent/CA2936974A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2936974A 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia Pending CA2936974A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3155599A CA3155599A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461929941P 2014-01-21 2014-01-21
US61/929,941 2014-01-21
US201461981033P 2014-04-17 2014-04-17
US61/981,033 2014-04-17
US201462069155P 2014-10-27 2014-10-27
US62/069,155 2014-10-27
PCT/US2015/012315 WO2015112642A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3155599A Division CA3155599A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Publications (1)

Publication Number Publication Date
CA2936974A1 true CA2936974A1 (en) 2015-07-30

Family

ID=52450623

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2936974A Pending CA2936974A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
CA3155599A Pending CA3155599A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3155599A Pending CA3155599A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Country Status (24)

Country Link
US (5) US20170020877A1 (2)
EP (2) EP3096756B1 (2)
JP (5) JP6585625B2 (2)
KR (2) KR102258522B1 (2)
CN (2) CN106102740A (2)
AU (4) AU2015209452C1 (2)
BR (1) BR112016016975B1 (2)
CA (2) CA2936974A1 (2)
DK (1) DK3096756T3 (2)
ES (1) ES2984706T3 (2)
FI (1) FI3096756T3 (2)
HR (1) HRP20241046T1 (2)
HU (1) HUE068315T2 (2)
IL (5) IL304134B2 (2)
LT (1) LT3096756T (2)
MX (3) MX389004B (2)
NZ (1) NZ722122A (2)
PL (1) PL3096756T3 (2)
PT (1) PT3096756T (2)
RS (1) RS65839B1 (2)
RU (1) RU2718918C2 (2)
SI (1) SI3096756T1 (2)
SM (1) SMT202400361T1 (2)
WO (1) WO2015112642A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951112B2 (en) 2021-04-12 2024-04-09 Maxim Masiutin Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65839B1 (sr) * 2014-01-21 2024-09-30 Neurocrine Biosciences Inc Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
EP3107569A4 (en) 2014-02-20 2018-02-21 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
JP7187037B2 (ja) 2016-09-07 2022-12-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｐ－タウを減少させ、認知機能を改善させるアロステリック副腎皮質刺激ホルモン放出因子受容体１（ＣＲＦＲ１）アンタゴニスト
WO2019036503A1 (en) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en) * 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
JP7532328B2 (ja) * 2018-12-07 2024-08-13 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
US20220023266A1 (en) * 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja) * 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
JP7623365B2 (ja) * 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
CR20220624A (es) * 2020-06-10 2023-07-06 Sanofi Sa Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4949582B1 (2) 1969-01-20 1974-12-27
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
DE69818248T2 (de) 1997-04-22 2004-06-17 Janssen Pharmaceutica N.V. Chinolin- und chinazolin-derivate als crf antagonisten
WO1999010350A1 (en) 1997-08-22 1999-03-04 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
CA2369553A1 (en) 1999-04-02 2000-10-12 Raymond F. Horvath N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
FR2796380B3 (fr) 1999-07-15 2001-08-17 Sanofi Synthelabo Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
US7276526B2 (en) 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
WO2005079807A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
EP1869049B1 (en) 2005-03-21 2009-03-04 Eli Lilly And Company Imidazopyridazine compounds
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
JPWO2006126718A1 (ja) 2005-05-27 2008-12-25 田辺三菱製薬株式会社 ピラゾロピリミジン誘導体
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2007069565A1 (ja) 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
JPWO2007069671A1 (ja) 2005-12-15 2009-05-21 小野薬品工業株式会社 二環式複素環化合物
PL1982178T3 (pl) 2006-02-07 2014-02-28 Phenoquest Ag Sposoby leczenia zaburzeń afektywnych
EP1834641A1 (en) 2006-03-16 2007-09-19 Sanofi-Aventis Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
HRP20100516T1 (hr) 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
JP5184536B2 (ja) 2006-09-20 2013-04-17 イーライ リリー アンド カンパニー チオフェンピラゾロピリミジン化合物
US20100056515A1 (en) 2006-10-25 2010-03-04 Kazuyoshi Aso Benzimidazole compounds
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
JP2010514672A (ja) 2006-12-29 2010-05-06 武田薬品工業株式会社 Ｃｒｆアンタゴニスト活性を有する縮合複素環化合物
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
WO2009008552A1 (en) 2007-07-11 2009-01-15 Taisho Pharmaceutical Co., Ltd. 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
WO2009144632A1 (en) 2008-05-30 2009-12-03 Pfizer Limited Novel compounds
US7932256B2 (en) 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
JP2011529899A (ja) 2008-07-31 2011-12-15 ブリストル−マイヤーズ スクイブ カンパニー 副腎皮質刺激ホルモン放出因子受容体活性のモジュレーターとしての置換カルバメート誘導体
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
JP5800428B2 (ja) 2008-11-03 2015-10-28 ジンテス ゲゼルシャフト ミット ベシュレンクテル ハフツング 調整式ロッド組立体
US8551996B2 (en) 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
HUP0900267A2 (en) 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
EP2487177A1 (en) 2009-10-08 2012-08-15 Eisai R&D Management Co., Ltd. Pyrazoloxazole compound
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
SG10201608579UA (en) 2012-04-13 2016-12-29 Epizyme Inc Combination therapy for treating cancer
US20150278438A1 (en) * 2012-04-23 2015-10-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists
US20150094310A1 (en) 2012-04-23 2015-04-02 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
RS65839B1 (sr) * 2014-01-21 2024-09-30 Neurocrine Biosciences Inc Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
WO2016065177A1 (en) 2014-10-22 2016-04-28 The Trustees Of The University Of Pennsylvania Method of treating depression and other stress related disorders
US9714246B2 (en) 2015-02-06 2017-07-25 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
EP3277836B1 (en) 2015-04-02 2019-02-27 HMNC Value GmbH Method of treatment using genetic predictors of a response to treatment with ssr-125543
WO2018012066A1 (ja) * 2016-07-14 2018-01-18 株式会社コナミデジタルエンタテインメント ゲームシステム、端末装置及びプログラム
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
WO2018219804A1 (en) 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Self-microemulsifying drug delivery systems
JP7285222B2 (ja) 2017-08-14 2023-06-01 スプルース バイオサイエンシズ インコーポレイテッド 副腎皮質刺激ホルモン放出因子受容体拮抗薬
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en) 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja) 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
TW202134241A (zh) 2019-12-04 2021-09-16 美商紐羅克里生物科學有限公司 Ｃｒｆ受體拮抗劑及使用方法
CR20220624A (es) 2020-06-10 2023-07-06 Sanofi Sa Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
US20240024330A1 (en) 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951112B2 (en) 2021-04-12 2024-04-09 Maxim Masiutin Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen

Also Published As

Publication number Publication date
AU2020207774A1 (en) 2020-08-06
HUE068315T2 (hu) 2024-12-28
FI3096756T3 (fi) 2024-08-14
US20190231781A1 (en) 2019-08-01
DK3096756T3 (da) 2024-08-05
IL304134B1 (en) 2024-12-01
AU2015209452B2 (en) 2020-05-07
AU2015209452C1 (en) 2020-11-05
KR20210064407A (ko) 2021-06-02
MX389004B (es) 2025-03-20
IL246783A0 (en) 2016-08-31
IL317035A (en) 2025-01-01
SMT202400361T1 (it) 2024-11-15
BR112016016975A2 (pt) 2017-08-08
MX2022000080A (es) 2022-02-03
US20170020877A1 (en) 2017-01-26
JP6936825B2 (ja) 2021-09-22
SI3096756T1 (sl) 2024-09-30
US20210137926A1 (en) 2021-05-13
RU2016133972A3 (2) 2018-09-26
IL246783B (en) 2021-10-31
NZ722122A (en) 2020-06-26
PL3096756T3 (pl) 2024-10-28
US10905690B2 (en) 2021-02-02
MX2021012539A (es) 2021-11-12
RU2718918C2 (ru) 2020-04-15
ES2984706T3 (es) 2024-10-30
CA3155599A1 (en) 2015-07-30
PT3096756T (pt) 2024-08-26
US20210361659A1 (en) 2021-11-25
US11311544B2 (en) 2022-04-26
IL296683B2 (en) 2023-12-01
IL296683B1 (en) 2023-08-01
MX2016009499A (es) 2017-02-27
JP2022010260A (ja) 2022-01-14
JP2024098001A (ja) 2024-07-19
IL286782A (en) 2021-10-31
LT3096756T (lt) 2024-08-26
RU2016133972A (ru) 2018-03-05
US11730739B2 (en) 2023-08-22
EP3096756B1 (en) 2024-06-12
JP2020138978A (ja) 2020-09-03
EP4450070A1 (en) 2024-10-23
AU2022263460B2 (en) 2024-10-17
AU2024219813A1 (en) 2024-10-10
IL304134B2 (en) 2025-04-01
JP6585625B2 (ja) 2019-10-02
US20240058342A1 (en) 2024-02-22
BR112016016975B1 (pt) 2022-12-27
KR20160106176A (ko) 2016-09-09
JP2017503030A (ja) 2017-01-26
EP3096756A1 (en) 2016-11-30
IL304134A (en) 2023-09-01
HRP20241046T1 (hr) 2024-11-08
RU2020112197A (ru) 2020-05-21
WO2015112642A1 (en) 2015-07-30
IL296683A (en) 2022-11-01
KR102258522B1 (ko) 2021-05-31
JP2019081814A (ja) 2019-05-30
JP7104743B2 (ja) 2022-07-21
AU2022263460A1 (en) 2022-12-08
AU2020207774B2 (en) 2022-08-04
CN106102740A (zh) 2016-11-09
CN111228274A (zh) 2020-06-05
RS65839B1 (sr) 2024-09-30
AU2015209452A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
AU2022263460B2 (en) CRF1 receptor antagonists for the treatment of congenital adrenal hyperplasia
HK40116454A (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
RU2812318C2 (ru) Антагонисты рецептора cfr1 для лечения врожденной гиперплазии коры надпочечников
HK40030956A (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
HK1231749A1 (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
HK1231749B (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
EP1842543A1 (en) Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200116

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D161 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PPH RETAINED AFTER REVIEW

Effective date: 20240828

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250117

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260116

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260116